Bharat Biotech raises Covaxin capacity by another 200 million doses a year
Production to take place in facility operated under its wholly owned subsidiary in Gujarat
Hyderabad-based Bharat Biotech is looking forward in ramping up its manufacturing capacity for Covaxin, its indigenous COVID-19 vaccine by another 200 million doses a year. The production of these doses are to be carried out using a facility in Gujarat currently operated by its wholly-owned subsidiary Chiron Behring Vaccines. The production for this facility will commence from fourth quarter in 2021. This effectively takes the Covaxin volume up to about one billion doses a year. The company is seeking for manufacturing partnerships to ramp up the production.